source
- Kyverna reports year-long efficacy and clean safety for miv-cel CAR-T in autoimmune trialsKyverna Therapeutics released one-year data for its CAR-T candidate miv-cel in stiff person syndrome and 18-month data in generalized myasthenia gravis. The single dose showed durable clinical ben…
- Boehringer Ingelheim boosts Variant Bio partnership with $250 million for cardiovascular researchBoehringer Ingelheim announced an expansion of its collaboration with Variant Bio. The partnership will now include cardiovascular disease research, broadening its original scope. The deal value…